Gainers
OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
Unyvero platform for rapid diagnostics to be used in Phase II clinical trial of BV100
Focus on the detection of pneumonia patients infected with Acinetobacter baumannii
ROCKVILLE, Md. and BASEL,